Similar content being viewed by others
This article is cited by
-
PANTHER: AZD8931, inhibitor of EGFR, ERBB2 and ERBB3 signalling, combined with FOLFIRI: a Phase I/II study to determine the importance of schedule and activity in colorectal cancer
British Journal of Cancer (2023)
-
Depleting receptor tyrosine kinases EGFR and HER2 overcomes resistance to EGFR inhibitors in colorectal cancer
Journal of Experimental & Clinical Cancer Research (2022)
-
HER3 in cancer: from the bench to the bedside
Journal of Experimental & Clinical Cancer Research (2022)
-
miR-199b-3p contributes to acquired resistance to cetuximab in colorectal cancer by targeting CRIM1 via Wnt/β-catenin signaling
Cancer Cell International (2022)
-
Molecular mechanism(s) of regulation(s) of c-MET/HGF signaling in head and neck cancer
Molecular Cancer (2022)